Transthyretin Amyloid Cardiomyopathy Clinical Trial
A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis
Summary
This study is testing a potential new medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis.The study will look at if this medicine can reduce the symptoms of a heart disease due to TTR amyloidosis, such as heart failure. Participants will either get NNC6019-0001 (apotential new medicine) or placebo (a medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting NNC6019-0001 is two times higher than getting placebo. NNC6019-0001 is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe yet. Participants will get an infusion of the study medicine 13 times, once every 4 weeks. The study will last for about 64 weeks after the first dose of medicine. Participants cannot participate in this study if they have a heart disease other than a heart disease due to TTR amyloidosis.
Eligibility Criteria
Inclusion Criteria:
Male or female.
Age greater than or equal to (>=) 18 to less than (<) 85 years at the time of signing informed consent.
Have an established diagnosis of Transthyretin amyloid cardiomyopathy (ATTR CM) with either wild-type transhyretin (TTR) or hereditary transthyretin (TTR) genotype as per local standards.
Expected to be on stable doses of cardiovascular medical therapy 6 weeks prior to the randomisation visit.
Known end-diastolic interventricular septal wall thickness greater than or equal to (>=) 12 millimeters (mm).
Presently classified as New York Heart Association (NYHA) Class II-III.
N-terminal-pro brain natriuretic peptide (NT-proBNP) concentration greater than or equal to (>=) 650 picograms per milliliter (pg/mL) in sinus cardiac rhythm and greater than (>) 1000 pg/mL in atrial fibrillation at screening.
Completed greater than or equal to (>=) 150 meters to less than or equal to (<=) 450 meters on the 6-minute walk test (MWT) at screening.
Estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 25 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2) at screening.
Exclusion Criteria:
Cardiomyopathy not primarily caused by transthyretin amyloid cardiomyopathy transthyretin amyloid cardiomyopathy (ATTR CM), for example, cardiomyopathy due to hypertension, valvular heart disease, or ischemic heart disease.
A prior solid organ transplant.
Planned solid organ transplant during the study.
Presence or history of malignant neoplasm (other than basal or squamous cell skin cancer, insitu carcinomas of the cervix, or in-situ/high grade prostatic intraepithelial neoplasia (PIN) or low-grade prostate cancer) within 5 years before screening.
Current treatment with calcium channel blockers with conduction system effects (example [e.g.], verapamil, diltiazem). The use of dihydropyridine calcium channel blockers is allowed. The use of digoxin will only be allowed if required for management of atrial fibrillation with rapid ventricular response.
Acute coronary syndrome, unstable angina, stroke, transient ischemic attack (TIA), coronary revascularization, cardiac valve repair, or major surgery within 3 months of screening.
Body weight >120 kilogram (kg) (264.6 pounds [lb]) at screening.
History of contrast allergy or adverse reactions to gadolinium-containing agents.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 29 Locations for this study
Phoenix Arizona, 85054, United States
Beverly Hills California, 90211, United States
Stanford California, 94305, United States
Jacksonville Florida, 32224, United States
Evanston Illinois, 60208, United States
Baltimore Maryland, 21201, United States
Rochester Minnesota, 55905, United States
Portland Oregon, 97239, United States
Calgary Alberta, T2N 4, Canada
Vancouver British Columbia, V5Z 1, Canada
Praha 2 , 12808, Czechia
Praha 2 , 12808, Czechia
Créteil , 94010, France
Toulouse Cedex 9 TSA 50032 , 31059, France
Heidelberg , 69120, Germany
München , 81377, Germany
Münster , 48149, Germany
Würzburg , 97078, Germany
Pavia , 27100, Italy
Fukuoka , 807-8, Japan
Hiroshima , 734-8, Japan
Kumamoto-shi, Kumamoto , 860-8, Japan
Nagano , 390-8, Japan
Nagasaki , 852-8, Japan
Okayama-shi, Okayama , 700-8, Japan
Groningen , 9713 , Netherlands
Utrecht , 3584 , Netherlands
Guimarães , 4835-, Portugal
Vila Real , 5000-, Portugal
Madrid , 28222, Spain
How clear is this clinincal trial information?